Sweet Science Lesson! See How Stem Cell Therapy Works
http://www.innovationsstemcellcenter.com Call: 214.420.7970 Facebook: https://www.facebook.com/innovationsmedical Twitter: https://twitter.com/dallasdrj Inst...
By: dallasdrj
Visit link:
Sweet Science Lesson! See How Stem Cell Therapy Works - Video
GTGP Dr Linzey Stem Cell Therapy
By: Mountain Television Network
More here:
GTGP Dr Linzey Stem Cell Therapy - Video
Othropedic Surgeon Dr. Propper Speaks about Stem Cell Therapy - PRP - BMAC
Orthopedic Surgeon Dr. Propper Speaks about the Difference of Stem Cell Injection Therapy PRP - BMAC.
By: Dennis Spoonhour, DC
Go here to see the original:
Othropedic Surgeon Dr. Propper Speaks about Stem Cell Therapy - PRP - BMAC - Video
6 hours ago
Johns Hopkins researchers have discovered an unexpected phenomenon in the organs that produce sperm in fruit flies: When a certain kind of stem cell is killed off experimentally, another group of non-stem cells can come out of retirement to replace them.
The discovery sheds light on the tiny "environments" that stem cells occupy in animal bodies and may help explain how stem cells in tumors replenish themselves, the researchers report in the May 8 issue of the journal Cell Reports. Damage of the kind duplicated in the laboratory occurs naturally after exposure to radiation and perhaps also after ingestion of toxic chemicals such as those used in chemotherapy.
The research group, led by Erika Matunis, Ph.D., a professor of cell biology at the Johns Hopkins University School of Medicine, has been using the fruit fly as a model living system in which to study stem cells in their natural state. Most stem cell research is done on cells grown in the laboratory, but in real life, stem cells reside in tissues, where they are sequestered in tiny spaces known as niches. Adult stem cells keep dividing throughout life to make various kinds of cells, like new blood cells and germ cells.
Matunis's group studies such niches in fruit fly testes, the sperm-producing organs shaped like a coiled tube whose end houses a niche. In the niche are three kinds of cells: germ line stem cells, which divide to produce sperm; somatic cyst stem cells, which make a kind of cell that helps the sperm-producing cells out; and hub cells, which make signals that keep the other two kinds of cells going.
The hub cells are not stem cells; they have settled on their final form, incapable of dividing further or changing their functionor so everyone thought.
However, in a bid to figure out what happens when the somatic cyst stem cells are killed off, Matunis suggested that graduate student Phylis Hti figure out how to best do away with them, thinking the task would be straightforward.
Instead, she says, "it took a lot of heroic, patient combinations" of different genes working together to kill the somatic cyst cells, Matunis says.
"When we finally figured out a way to kill all of the somatic stem cells, we thought that the rest of the tissue would probably just empty out," she says. In 35 percent of testes, that's just what happened. But in the rest, the somatic stem cells grew back.
This was a surprise, Matunis says, and left a puzzle: Where were the new somatic stem cells coming from?
Read this article:
Surprise: Lost stem cells naturally replaced by non-stem cells, fly research suggests
St. Petersburg, FL (PRWEB) April 17, 2014
One of the most respected plastic surgeons in America is encouraging the FDA to move forward on approval of stem-cell based therapies inspired in part by Matthew McConaughey's recent Oscar win for the film Dallas Buyers Club. In the film, McConaughey portrayed Ron Woodroof, who fought the Food and Drug Administration over his use and distribution of unapproved but effective HIV/AIDS medications. In a letter to FDA comissioner Margaret A. Hamburg dated April 14th, Dr. Christian Drehsen of St. Petersburg claims that the story echoes current FDA treatment of stem cell therapies, of which almost none are approved for use in the United States.
Drehsen cites his extensive past experience working with stem cells, and calls on the FDA to provide more rapid approval for the procedures, which he says are safe and effective.
In the period 2009-2010, before the current regulatory embargo, Drehsen performed over 20 reconstructive and cosmetic stem-cell procedures using technology from the pioneering stem cell therapy research firm Cytori. In his letter, Drehsen writes that the results of his procedures were excellent, and hes frustrated with the limitations now in place.
Japan has approved these procedures. Much of Europe has approved them. Theyre changing peoples lives every day but not in the United States, the letter reads in part.
Stem cell therapies have myriad potential uses. Drehsen says that in his own practice at the Clinique of Plastic Surgery, their promise includes greatly improved outcomes for burn victims, patients with extensive sun exposure damage, and post-operative breast reconstruction procedures. Those therapies have been pioneered with good results in Europe and Australia, respectively.
Other treatments currently proven or under trial include treatments for traumatic hamstring injury (http://ir.cytori.com/investor-relations/News/news-details/2014/Cytori-to-Initiate-US-Clinical-Trial-of-Adipose-Derived-Regenerative-Cells-in-Hamstring-Injuries/default.aspx) and chronic heart failure (http://www.cytori.com/Innovations/ClinicalTrials/CardiovascularDisease.aspx).
Though much American resistance to stem cell research has been rooted in ethical concerns about the use of embryonic stem cells, the Cytori procedure uses Adipose-Derived Regenerative Cells, or ADRCs stem cells derived from the patients own body fat and altered for re-injection using a proprietary process. Dr. Drehsen was one of a handful of doctors in the United States to use this technology for plastic surgery before the FDA blocked its usage. This makes him one of the most experienced surgeons in the U.S. in non-embryonic stem-cell enhanced facelift procedures. Drehsens website (http://cliniqueps.com) features many examples of his past successful stem-cell procedure outcomes.
The FDA serves the vital function of ensuring patient safety. But these procedures have been proven safe," Drehsen concludes. "It should be no surprise that using a patients own tissue presents fewer risks than many alternatives. Its sad that these options have continued to be blocked by bureaucracy.
Drehsen says that much of the equipment used in his stem cell procedures now sits in storage, unused.
Continue reading here:
St. Petersburg Surgeon Dr. Christian Drehsen Lobbies FDA to Speed Approval of Non-Embryonic Stem Cell Therapy
Stem Cell Therapy Can Reverse the Effects of Spinal Disc Degeneration
See how Duke University researchers discovered a better delivery system for stem cell therapy. Spinal disc degeneration is a common problem as one ages and c...
By: Adam Bieber
More here:
Stem Cell Therapy Can Reverse the Effects of Spinal Disc Degeneration - Video
Diff bw Surgical Hair Transplantaion Stem Cell Therapy - Health file
Subscribe to Tv5 News Channel: http://goo.gl/NHJD9 Like us on Facebook: http://www.facebook.com/tv5newschannel Follow us on Twitter: https://twitter.co...
By: TV5 News
Read more from the original source:
Diff bw Surgical Hair Transplantaion & Stem Cell Therapy - Health file - Video
Two Central Pennsylvania dogs are receiving a regenerative therapy for arthritis thats unprecedented for this area and less expensive than standard surgery. Stem Cell therapy is a way to repair damaged tissue and treat injury. When dealing with dogs, veterinarians say its the future of treatments and its becoming less costly.
Gunny is a 7-year-old German Shepard. He underwent the revolutionary stem cell therapy at the Palmyra Animal Clinic. Vets say the stem cell therapy is a way to combat Gunnys arthritis in his hips. Doctors collected fatty tissue from his shoulder, processed the stem cells in the lab and injected the cells back into his hips. This happens all in one day for around $1500. Prior to this, surgery could cost around $3,000.
Dr. Calvin Clements of the Palmyra Animal Clinic says, Injected in a damaged joint or ligament, these cells will take on that characteristic and differentiate into the cartilage or tissue were dealing with and help to regenerate it.
Dr. Clements says results are noticeable in about a month. On average, animals improve 85%.
For more information, contact the Palmyra Animal Clinic at 717-838-5451.
To learn more click here.
See original here:
Stem cell scientist Mahendra Rao, former director of the now-defunct Center For Regenerative Medicine at the National Institutes of Health. Photo taken in December, 2013 during a speech by Rao at the World Stem Cell Summit in San Diego.
One of the nation's top stem cell scientists has become an adviser to San Diego's Stemedica, a developer of stem cell-based therapies.
Dr. Mahendra Rao joined Stemedica's scientific and medical advisory board, and will help guide the company's strategy, said Maynard Howe, chief executive of the privately held company. Rao's career as a scientist who has also worked for companies and federal agencies makes him particularly useful, Howe said.
Rao is a medical doctor with a PhD in developmental neurobiology from CalTech. He headed the neurosciences division of the National Institute on Aging. He also led the stem cell division of Carlsbad-based Life Technologies, now a unit of Thermo Fisher Scientific. The two companies are on good terms: Life Technologies sells two kinds of stem cells made by Stemedica, used for research purposes, Howe said.
Rao was most recently founding director of the Center for Regenerative Medicine at the National Institutes of Health, which has been shut down. Rao, who resigned at the end of March, said he was disappointed at the slow pace of funding studies with artificial embryonic stem cells, called induced pluripotent stem cells. Stemedica announced his appointment April 8.
Rao said Wednesday that his goal now is to advance stem cell therapies through the private sector. Stemedica drew his attention because it had developed a method of reliably generating "clinically compliant" stem cells suitable for use in therapy.
In addition, Rao said he likes that Stemedica is developing combination stem cell therapies, using a variety called mesenchymal stem cells. This variety of stem cell generates chemicals that promote short-term regrowth and seems to enhance the survival of other transplanted stem cells. For example, mesenchymal stem cells could help transplanted neural stem cells integrate into the brain.
"That's a high-risk process and it's a much more difficult road, but they seem to be willing to do that," Rao said.
He has also rejoined the board of Q Therapeutics, a Salt Lake City company developing treatments for spinal cord injuries and other neurological disorders. Rao is the company's scientific founder, but had to leave the company when he joined the NIH.
Stemedica and its affiliated companies are undertaking multiple clinical trials of stem cell therapies. One of the most advanced is for stroke, Howe said. See utsandiego.com/stemedicastroke1 for detailed information.
The rest is here:
PALMYRA -- Gunny, an 8-year-old German shepherd, who has been suffering from painful arthritis in his hips, got a new lease on life Wednesday after receiving an injection of stem cells from his own body.
Gunny was the first of two dogs with degenerative joint disease who were treated with a new, faster and less expensive procedure at the Palmyra Animal Clinic, 920 E. Main St. The new process, which is available for dogs, cats and horses, uses stem cells taken from fatty tissue in the animals to combat osteoarthritis to improve their quality of life.
The process has been around for a decade, but with new technology, the local clinic is able to do the process in-house, in less time and at less cost. The clinic has been offering stem cell therapy since 2008.
While stem cell therapy has been commercially available for about a decade, Dr. Calvin Clements, owner of the clinic, said, "there was a several-day turnaround, multiple anesthesias, and it was considerable expense. With this technique, we have the ability to collect the cells, inject the cells and bank the cells."
The cost of the procedure is about $1,300, compared to $3,000 when sent out of house, Clements said.
On mobile? Click here to view photo gallery
On Wednesday, Clements and his associate, Dr. Richard Hann, used the new process - known as Adipose-Derived Stem Cell Procedure - for the first time in their office with Gunny, and Hudson, an 8-year-old toy fox terrier, who has arthritis in his knees.
Clements said an animal's pain from degenerative disease is similar to humans.
"Like the pain that anyone who has advanced joint degenerative disease experiences, at first, it doesn't hurt too bad but as time progresses some are in considerable pain. It can be very severe," he said.
"We're looking to improve their joint function. Stem cell therapy has really proven itself just by the outcome that we've had in patients when we were shipping it out," Clements said. "This is more convenient. It's a faster process. It's in-house, and we know how the samples are being handled from beginning to end."
Read this article:
Palmyra Animal Clinic adds new stem cell therapy to improve animals' lives
Updated: Wednesday, April 16 2014, 06:10 PM CDT It's like a new lease on life for some pets in Lebanon County, after they got an improved type of stem cell therapy.
Gunney is an 8-year-old German Shepherd, suffering with severe hip pain. Doctor Calvin Clements is treating the dog with a new type of stem cell therapy, where cells are collected, harvested, and injected. This is all done in the Palmyra Office and all done on the same day.
This takes out the practice of shipping out the tissues and waiting days to get the cells back. In the end, it allows the animals to feel better, faster.
It will take Gunney just a few days to start feeling better, but a full month before the cells fully take. According to Doctor Calvin Clements, this therapy improves the animal's health by 85%.Palmyra vet treats dogs with stem cell therapy
See the article here:
Advanced Cell Technology is testing a stem-cell treatment for blindness that could preserve vision and potentially reverse vision loss.
Vision support: The cells used in Advanced Cell Technologys clinical trials produce dark pigments and cobblestone-like patterns that can be readily recognized in cultures.
A new treatment for macular degeneration is close to the next stage of human testinga noteworthy event not just for the millions of patients it could help, but for its potential to become the first therapy based on embryonic stem cells.
This year, the Boston-area company Advanced Cell Technology plans to move its stem-cell treatment for two forms of vision loss into advanced human trials. The company has already reported that the treatment is safe (see Eye Study Is a Small but Crucial Advance for Stem-Cell Therapy), although a full report of the results from the early, safety-focused testing has yet to be published. The planned trials will test whether it is effective. The treatment will be tested both on patients with Stargardts disease (an inherited form of progressive vision loss that can affect children) and on those with age-related macular degeneration, the leading cause of vision loss among people 65 and older.
The treatment is based on retinal pigment epithelium (RPE) cells that have been grown from embryonic stem cells. A surgeon injects 150 microliters of RPE cellsroughly the amount of liquid in three raindropsunder a patients retina, which is temporarily detached for the procedure. RPE cells support the retinas photoreceptors, which are the cells that detect incoming light and pass the information on to the brain.
Although complete data from the trials of ACTs treatments have yet to be published, the company has reported impressive results with one patient, who recovered vision after being deemed legally blind. Now the company plans to publish the data from two clinical trials taking place in the U.S. and the E.U. in a peer-reviewed academic journal. Each of these early-stage trials includes 12 patients affected by either macular degeneration or Stargardts disease.
The more advanced trials will have dozens of participants, says ACTs head of clinical development, Eddy Anglade. If proved safe and effective, the cellular therapy could preserve the vision of millions affected by age-related macular degeneration. By 2020, as the population ages, nearly 200 million people worldwide will have the disease, estimate researchers. Currently, there are no treatments available for the most common form, dry age-related macular degeneration.
ACTs experimental treatment has its origins in a chance discovery that Irina Klimanskaya, the companys director of stem-cell biology, made while working with embryonic stem cells at Harvard University. These cells have the power to develop into any cell type, and in culture they often change on their own. A neuron here, a fat cell thereindividual cells in a dish tend to take random walks down various developmental paths. By supplying the cultures with fresh nutrients but otherwise leaving them to their own devices for several weeks, Klimanskaya discovered that the stem cells often developed into darkly pigmented cells that grew in a cobblestone-like pattern. She suspected that they were developing into RPE cells, and molecular tests backed her up.
Now that her discovery has advanced into an experimental treatment, Klimanskaya says she is excited by the hints that it may be able to preserve, and perhaps restore, sight. She recalls a voice mail she received during her second year at ACT: a person blinded by an inherited condition thanked her for her work, whether or not there was a treatment available for him. When you get a message like this, you feel like you are not doing it in vain, she says.
Original post:
Stem-Cell Treatment for Blindness Moving Through Patient Testing
PALMYRA -- Gunny, an 8-year-old German shepherd, who has been suffering from painful arthritis in his hips, got a new lease on life Wednesday after receiving an injection of stem cells from his own body.
Gunny was the first of two dogs with degenerative joint disease who were treated with a new, faster and less expensive procedure at the Palmyra Animal Clinic, 920 E. Main St. The new process, which is available for dogs, cats and horses, uses stem cells taken from fatty tissue in the animals to combat osteoarthritis to improve their quality of life.
The process has been around for a decade, but with new technology, the local clinic is able to do the process in-house, in less time and at less cost. The clinic has been offering stem cell therapy since 2008.
While stem cell therapy has been commercially available for about a decade, Dr. Calvin Clements, owner of the clinic, said, "there was a several-day turnaround, multiple anesthesias, and it was considerable expense. With this technique, we have the ability to collect the cells, inject the cells and bank the cells."
The cost of the procedure is about $1,300, compared to $3,000 when sent out of house, Clements said.
On mobile? Click here to view photo gallery
On Wednesday, Clements and his associate, Dr. Richard Hann, used the new process - known as Adipose-Derived Stem Cell Procedure - for the first time in their office with Gunny, and Hudson, an 8-year-old toy fox terrier, who has arthritis in his knees.
Clements said an animal's pain from degenerative disease is similar to humans.
"Like the pain that anyone who has advanced joint degenerative disease experiences, at first, it doesn't hurt too bad but as time progresses some are in considerable pain. It can be very severe," he said.
"We're looking to improve their joint function. Stem cell therapy has really proven itself just by the outcome that we've had in patients when we were shipping it out," Clements said. "This is more convenient. It's a faster process. It's in-house, and we know how the samples are being handled from beginning to end."
Follow this link:
Palmyra Animal Clinic adds new stem cell therapy to improve animals' lives
Sam Harrell #39;s Stem Cell Journey: Stem Cell Therapy for Multiple Sclerosis
Sam Harrell sent us this homemade video documenting his progress from 2010 until now (2014). Sam was coaching football at Ennis high school in Texas when MS ...
By: http://www.cellmedicine.com
Read the original:
Sam Harrell's Stem Cell Journey: Stem Cell Therapy for Multiple Sclerosis - Video
Washington (PRWEB) April 15, 2014
Research that resulted in the first stem cells that are pluripotentthose that have the potential to differentiate into almost any cell in the bodywill be the backdrop for a discussion about trends in regulation in the field of regenerative medicine at the DIA 2014 50th Annual Meeting, June 15 to 19 in San Diego.
Chaired by Shinji Miyake, professor of clinical research for the Keio University School of Medicine in Japan, the session Pioneering Regenerative Medicine: Trends in Regulations for New Therapy will introduce the worlds first clinical research of induced pluripotent stem (iPS) cell products, conducted in Japan, and review updated regulatory guidance to bring regenerative medicine to patients who need healthy tissue or organs. The session will be held June 16 at 8:30 a.m. in the San Diego Convention Center.
iPS cells are stem cells that can be generated directly from adult cells. These cells can multiply indefinitely and represent a single source of cells, such as heart, neural, pancreatic and liver, that can be used to replace damaged cells.
In 2006, Japanese physician and researcher Shinya Yamanaka led a team to generate iPS cells from adult mouse tissue using gene therapy. This work led to a Nobel Prize in Physiology or Medicine in 2012 for the discovery that mature cells can be reprogrammed to become pluripotent.
We are honored to host pioneers of this unique field of medicine at the DIA Annual Meeting to share their experiences in the planning of the first clinical research of iPS cell productswhich have the ability to enhance research worldwide, said Barbara L. Kunz, DIA global chief executive. Their expert knowledge of issues and solutions in the application of the regenerative therapies will benefit all who advocate for and drive innovative medicine.
The session will also feature a presentation about the application of iPS cells to retinal diseases by Masayo Takahashi, project leader for the RIKEN Center for Developmental Biology in Japan, along with a European Medicines Agency (EMA) presentation by Dariusz Sladowski, researcher and member of the Committee for Advanced Therapies at EMA.
ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIAs network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Pa., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit http://www.diahome.org.
ABOUT DIAs 2014 50th ANNUAL MEETING: Celebrate the Past Invent the Future is the largest multidisciplinary event that brings together a community of life sciences professionals at all levels and across all disciplines involved in the discovery, development and life cycle management of medical products. The meeting aims to foster innovation that will lead to the development of safe and effective medical products and therapies for patients. For more information, visit http://www.diahome.org/dia2014.
The rest is here:
Pioneers in Regenerative Therapy to Discuss New Trends in Stem Cell Medicine
ReNeuron Group Quote more
Price: 2.98
Chg: -0.07
Chg %: -2.30%
Date: 16:51
AIM-listed ReNeuron has signed a deal with the Welsh government to lease a landmark building at Pencoed Technology Park, near Cardiff in South Wales.
The stem cell therapy company explained that it will build a new state-of-the-art facility at Pencoed, to which it will relocate the business next year.
The move will unite various elements of the firm's business activities in a single location, which it said would provide operational synergies to aid therapeutic candidates as they move through clinical development to future market approval.
ReNeuron said it expects the move will create up to another 70 jobs at the site in the next two years.
Michael Hunt, Chief Executive Officer of ReNeuron, said: "We are delighted to have signed an agreement to lease this landmark building in South Wales, which marks a further significant step in ReNeuron's business development strategy. When complete, we believe the building will house the UK's most advanced commercial cell therapy manufacturing facility and we are delighted to continue to work with the Welsh government to bring this important project to fruition.
Visit link:
Trinity final
At the Trinity Stem Cell Institute our medical team is among the most renowned in the world for their research and development of stem cell therapy for back ...
By: SMU Productions - Tampa Video Production
Read the original:
Trinity final - Video
By Estel Grace Masangkay
Bone marrow stem cells may help in stroke recovery, according to a team of researchers from the University of California, Irvines Sue and Bill Gross Stem Cell Research Center.
Neurologist Dr. Steven Cramer and biomedical engineer Weian Zhao together analyzed 46 studies evaluating the use of a type of multipotent adult stem cells mostly processed from the bone marrow called mesenchymal stromal cells (MSC) in animal models of stroke. Results showed that MSCs were superior to control therapy in 44 out of the 46 studies.
Dr. Cramer said Stroke remains a major cause of disability, and we are encouraged that the preclinical evidence shows [MSCs] efficacy with ischemic stroke. MSCs are of particular interest because they come from bone marrow, which is readily available, and are relatively easy to culture. In addition, they already have demonstrated value when used to treat other human diseases.
The MSCs effect on functional recovery was shown to be robust regardless of other factors such as dosage, time of administration relative to the stroke onset, or administration method. An earlier report focusing on MSC mechanisms of action explained how the cells were attracted to the injury sites and began releasing a wide range of molecules in response to signals emitted by the damaged areas. The molecules in turn stimulate several activities including blood vessel creation for enhanced circulation, protection of vulnerable cells, brain cell growth, and others. The MSCs also fostered an environment conducive to brain repair.
We conclude that MSCs have consistently improved multiple outcome measures, with very large effect sizes, in a high number of animal studies and, therefore, that these findings should be the foundation of further studies on the use of MSCs in the treatment of ischemic stroke in humans, said Dr. Cramer.
The UCI teams analysis appeared in the April 8 issue of Neurology.
See original here:
UCI Team Discovers Bone Marrow Stem Cells' Potential In Stroke Recovery
Trinity Stem Cell Institute
At the Trinity Stem Cell Institute our medical team is among the most renowned in the world for their research and development of stem cell therapy for back ...
By: SMU Productions - Tampa Video Production
Go here to see the original:
By Estel Grace Masangkay
Bone marrow stem cells may help in stroke recovery, according to a team of researchers from the University of California, Irvines Sue and Bill Gross Stem Cell Research Center.
Neurologist Dr. Steven Cramer and biomedical engineer Weian Zhao together analyzed 46 studies evaluating the use of a type of multipotent adult stem cells mostly processed from the bone marrow called mesenchymal stromal cells (MSC) in animal models of stroke. Results showed that MSCs were superior to control therapy in 44 out of the 46 studies.
Dr. Cramer said Stroke remains a major cause of disability, and we are encouraged that the preclinical evidence shows [MSCs] efficacy with ischemic stroke. MSCs are of particular interest because they come from bone marrow, which is readily available, and are relatively easy to culture. In addition, they already have demonstrated value when used to treat other human diseases.
The MSCs effect on functional recovery was shown to be robust regardless of other factors such as dosage, time of administration relative to the stroke onset, or administration method. An earlier report focusing on MSC mechanisms of action explained how the cells were attracted to the injury sites and began releasing a wide range of molecules in response to signals emitted by the damaged areas. The molecules in turn stimulate several activities including blood vessel creation for enhanced circulation, protection of vulnerable cells, brain cell growth, and others. The MSCs also fostered an environment conducive to brain repair.
We conclude that MSCs have consistently improved multiple outcome measures, with very large effect sizes, in a high number of animal studies and, therefore, that these findings should be the foundation of further studies on the use of MSCs in the treatment of ischemic stroke in humans, said Dr. Cramer.
The UCI teams analysis appeared in the April 8 issue of Neurology.
View post:
UCI Team Discovers Bone Marrow Stem Cells' Potential In Stroke Recovery